Investigational drug · Phase 3
Roxadustat
Also called: FG-4592, ASP1517, Evrenzo
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Kidney Disease, Renal Anemia, Myelodysplastic Syndromes.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
67
Any phase or sponsor naming "Roxadustat"
First trial start
2024
Jan 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Roxadustat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Kidney Disease
- Renal Anemia
- Myelodysplastic Syndromes
Approved drugs for the same conditions: Myelodysplastic syndromes · Anemia · Chronic kidney disease · Hematology and blood cancers · Rare and genetic disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Roxadustat" as an intervention, largest first.
- Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on DialysisPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02174627 · 2,781 participants · Start Jun 26, 2014 · Primary completion Oct 4, 2018
Drug: Roxadustat; Placebo · For: Anemia
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 359 sites in all
- Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02174731 · 2,133 participants · Start Jul 1, 2014 · Primary completion Sep 26, 2018
Drug: Roxadustat; Epoetin alfa · For: Anemia
Sites: Huntsville, Alabama; El Centro, California; Fairfield, California · 188 sites in all
Astellas Pharma IncAstellas (ALPMY)
NCT04408820 · 2,104 participants · Start Jun 1, 2020 · Primary completion Jun 23, 2025
Drug: Roxadustat · For: Renal Anemia
Sites: Aichi, Japan; Akita, Japan; Aomori, Japan · 47 sites in all
- Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis ParticipantsPivotal-lookingCompleted
Kyntra BioIndustry
NCT02052310 · 1,043 participants · Start Feb 11, 2014 · Primary completion Sep 21, 2018
Drug: Roxadustat; Epoetin Alfa · For: Anemia in Incident Dialysis Patients
Sites: Chula Vista, California; La Mesa, California; San Diego, California · 113 sites in all
- A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving DialysisPivotal-lookingCompleted
Kyntra BioIndustry
NCT01750190 · 922 participants · Start Nov 5, 2012 · Primary completion Sep 24, 2018
Drug: Roxadustat; Placebo · For: CKD Anemia
Sites: Huntsville, Alabama; Tempe, Arizona; Alhambra, California · 145 sites in all
- Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable DialysisPivotal-lookingCompleted
Astellas Pharma Europe B.V.Astellas (ALPMY)
NCT02278341 · 838 participants · Start Nov 21, 2014 · Primary completion Jun 8, 2017
Drug: Roxadustat; Epoetin alfa and 2 more · For: Anemia; End Stage Renal Disease (ESRD)
Sites: Brussels, Belgium; Aalst, Belgium; Antwerp, Belgium · 143 sites in all
- Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable DialysisPivotal-lookingCompleted
Kyntra BioIndustry
NCT02273726 · 741 participants · Start Jan 15, 2015 · Primary completion Sep 19, 2018
Drug: Epoetin Alfa; Roxadustat · For: CKD Anemia in Stable Dialysis Patients
Sites: Phoenix, Arizona; Pine Bluff, Arkansas; Chula Vista, California · 76 sites in all
- Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin AlfaPivotal-lookingCompleted
Astellas Pharma Europe B.V.Astellas (ALPMY)
NCT02021318 · 616 participants · Start Mar 12, 2014 · Primary completion Mar 23, 2018
Drug: Roxadustat; Darbepoetin alfa · For: Anemia in Chronic Kidney Disease in Non-dialysis Patients
Sites: Vienna, Austria; Brest, Belarus; Grodno, Belarus · 125 sites in all
- Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring DialysisPivotal-lookingCompleted
Astellas Pharma Europe B.V.Astellas (ALPMY)
NCT01887600 · 594 participants · Start Sep 3, 2013 · Primary completion Nov 1, 2017
Drug: Roxadustat; Placebo · For: Anemia in Chronic Kidney Disease in Non-dialysis Patients
Sites: Brest, Belarus; Grodno, Belarus; Homyel, Belarus · 138 sites in all
- A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With AnemiaPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT02988973 · 334 participants · Start Jan 12, 2017 · Primary completion Sep 13, 2019
Drug: roxadustat; DA · For: Chronic Kidney Disease
Sites: Kasugai, Japan; Nagoya, Japan; Toyohashi, Japan · 66 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of roxadustat for the treatment of renal anemia in patients undergoing peritoneal dialysis: a systematic review and meta-analysis.
Zhou Y, Liao J, Huang W, et al. · Ren Fail 2026
- Initial side effects of roxadustat on thyroid function in patients undergoing hemodialysis.
Yamada H, Yuasa R, Koibuchi K, et al. · Ren Fail 2026
- Roxadustat attenuates contrast-induced acute kidney injury potentially mediated via the Nrf2/HO-1 signaling pathway.
Wang J, E JW, Zhang J · Ren Fail 2026
- Efficacy and safety of prolyl hydroxylase inhibitors for anemia in chronic kidney disease: a network meta-analysis.
Niu Y, Wang T, Zhan Y, et al. · Ren Fail 2026
- Roxadustat for treatment of suspected erythropoietin(EPO)-induced pure red cell aplasia in a hemodialysis patient: a case report.
Jiang S, Zhou Y, Xie Y, et al. · Naunyn Schmiedebergs Arch Pharmacol 2026
- Roxadustat ameliorates bone microarchitectural deterioration in CKD-MBD rats in association with mitigated systemic micro-inflammation and restored FGF23-Wnt/β-catenin signaling.
Shan Z, Liu Y, Sun X, et al. · Front Pharmacol 2026
Also in development for Chronic Kidney Disease
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- HRS-1780Phase 33 trials
Shandong Suncadia Medicine Co., Ltd. · Chronic Kidney Disease, Uncontrolled or Resistant Hypertension, Primary Aldosteronism
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Astellas.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.